A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS

BACKGROUND: In both the UNITI-1&2 Crohn’s disease (CD) studies, a single 6mg/kg Ustekinumab (UST) IV infusion showed significantly greater rates of clinical response & remission vs placebo, and significant reductions in CDAI (and >70 pt reduction)(1) by the first post-baseline visit at Wk...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Can Assoc Gastroenterol
Auteurs principaux: Sandborn, W, Yeager, B, Gasink, C, Hoops, T, Gao, L, Wang, Y, Jacobstein, D, Lee, S D, Hanauer, S
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Paper Sessions
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508147/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.108
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires